NCT02172573已完成3 期
A Double-blind, Placebo-controlled, Randomised, Multicenter Trial to Compare the Safety and Efficacy of Oral Administration of Pramipexole up to 4.5mg and Bromocriptine up to 22.5mg Combined With L-dopa in Advanced Parkinson's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 315
- 主要终点
- Change from baseline in total score of UPDRS Part III (Motor Examination)
研究概览
简要总结
The objective of the study was to evaluate the efficacy and safety of SND 919 (pramipexole) tablets administered in combination with L-dopa in patients with Parkinson's disease using placebo and bromocriptine tablets as comparators in a double-blind design (phase III comparative study).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with a diagnosis of Parkinson's disease (including juvenile parkinsonism)
- •Patients who meet all of the following inclusion criteria
- •Patients who were at least 20 years of age
- •In- or outpatients of either sex
- •Patients in any stage on the modified Hoehn and Yahr scale
- •Patients being treated with L-dopa who have any of the following clinical conditions and problems
- •Patients with the wearing-off phenomenon
- •Patients with the on-off phenomenon
- •Patients to whom a sufficient amount of L-dopa cannot be administered owing to the occurrence of an adverse event
- •Patients in whom the effect of L-dopa is attenuated
- •Patients in whom a dose increase of L-dopa has been refrained
- •Patients with freezing phenomenon
排除标准
- •Patients being treated with other dopamine agonists (bromocriptine, pergolide mesylate, talipexole hydrochloride). Patients who have been treated with other dopamine agonist for at least 4 weeks before the start of the study (the day of giving informed consent) are eligible for the study
- •Patients with a history of hypersensitivity to ergot preparations
- •Patients with psychiatric symptoms such as confusion, hallucination, delusion, excitement, delirium, and abnormal behaviour
- •Patients with subjective symptoms derived from orthostatic hypotension
- •Patients with hypotension (systolic blood pressure less than 100 mmHg)
- •Patients wiht Raynaud disease
- •Patients with peptic ulcer
- •Patients with complications such as severe cardiac, renal, hepatic disease etc.
- •Patients with a current or past history of epilepsy
- •Women who are or may be pregnant and lactating women
- •Patients who are receiving any other investigational products or who have received any other investigational product within 6 months of the study
- •Patients who are incompetent to give consent
- •Others judged by the investigator or co-investigator to be ineligible as subjects
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo pramipexole (Drug)
Placebo
Placebo Comparator
干预措施: Placebo bromocriptine (Drug)
Pramipexole
Experimental
干预措施: Pramipexole (Drug)
Bromocriptine
Experimental
干预措施: Bromocriptine (Drug)
结局指标
主要结局
Change from baseline in total score of UPDRS Part III (Motor Examination)
时间窗: Baseline and week 12
Change from baseline in total score of the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living)
时间窗: Baseline and week 12
次要结局
- Changes from baseline in scores of individual items on UPDRS Part III(Baseline and weeks 2, 4, 6, 8, 10, 12)
- Number of patients with abnormal changes in laboratory parameters(up to 12 weeks)
- Number of patients with abnormal changes in 12-lead electrocardiogram (ECG)(up to 12 weeks)
- Change from baseline in total score of UPDRS Part I-IV(Baseline and weeks 2, 4, 6, 8, 10, 12)
- Changes from baseline in sores of individual items on UPDRS Part II(Baseline and weeks 2, 4, 6, 8, 10, 12)
- Change from baseline in total score of UPDRS Part I (mentation, behaviour and mood)(Baseline and weeks 2, 4, 6, 8, 10, 12)
- Change from baseline in total score of UPDRS Part IV (complications of therapy)(Baseline and weeks 2, 4, 6, 8, 10, 12)
- Change from baseline in area under the curve (AUC) in the UPDRS Part II score(Baseline and weeks 2, 4, 6, 8, 10, 12)
- Change from baseline in Modified Hoehn & Yahr stage(Baseline and weeks 2, 4, 6, 8, 10, 12)
- Clinical global impression of efficacy(week 12)
- Number of patients with adverse events(up to 16 weeks)
- Number of patients with clinically significant changes in vital signs (blood pressure, pulse rate)(up to 12 weeks)
- Change from baseline in area under the curve (AUC) in the UPDRS Part III score(Baseline and weeks 2, 4, 6, 8, 10, 12)
- Change from baseline in total score of UPDRS Part I-III(Baseline and weeks 2, 4, 6, 8, 10, 12)
研究者
相似试验
已完成
3 期
Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's DiseaseParkinson DiseaseNCT00240409Boehringer Ingelheim208
已完成
3 期
First Time Use of SD-809 in Huntington DiseaseChoreaNCT01795859Teva Branded Pharmaceutical Products R&D, Inc.90
已完成
2 期
A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction ProcedureSedationPainAnxietyNCT00894699Talphera, Inc40
终止
1 期
BMS-986325 in Healthy Participants and Participants With Primary Sjögren's SyndromeHealthy ParticipantsPrimary Sjögren's SyndromeNCT04684654Bristol-Myers Squibb118
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy ParticipantsHealthy ParticipantsNCT04736134Bristol-Myers Squibb88